🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing globally, with estimates suggesting over 82 million new cases annually. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in the same week. This drug, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Results and Global Access

Based on results released by a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The research included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors directly involved have expressed positive views. Having a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is deemed vital to alleviate the strain of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea globally.